<DOC>
	<DOCNO>NCT03014076</DOCNO>
	<brief_summary>The purpose trial determine combination immunotherapy HER2/neu GP2 peptide + GM-CSF vaccine trastuzumab safe immunologically effective treatment patient HER2/neu over-expressing breast cancer adjuvant setting . While primary endpoint , time recurrence measure enrolled subject . The objective study follow : - Assess safety document local systemic toxicity combination immunotherapy GP2 peptide + GM-CSF vaccine trastuzumab - Evaluate vitro vivo immunologic response combination immunotherapy GP2 peptide + GM-CSF vaccine trastuzumab - Determine maximum tolerate dose optimal biologic dose combination immunotherapy GP2 peptide + GM-CSF vaccine trastuzumab</brief_summary>
	<brief_title>Immunotherapy Vaccine Herceptin Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Age &gt; 18 year HER2/neu+ overexpressing breast cancer ( IHC 3+ FISH ≥2.0 ) Patients receive adjuvant trastuzumab standard care treatment Completion breast cancer therapy ( i.e. , surgery , radiation , chemotherapy appropriate per standard care patient ' specific cancer ) exclude trastuzumab ( Patients oral hormonal therapy part adjuvant breast cancer treatment maintain regimen . ) Enrollment must occur patient ' trastuzumab treatment vaccine schedule overlap 6 vaccination first vaccination occur standard care Multiple Gated Acquisition Scan ( MUGA ) ECOG performance status ( PS ) 01 Clinically cancerfree ( evidence disease ; exclude +CTC ) If patient childbearing potential , must willing practice adequate contraception study treatment period 2 month completion injection sit Ability understand willingness sign write informed consent document Clinical and/or radiographic evidence residual persistent breast cancer Receiving immunosuppressive therapy include methotrexate steroid ( note : use prednisone , equivalent , &lt; 2.0mg/day , allow ) Tbili &gt; 1.8 , creatinin &gt; 2 , hemoglobin &lt; 10 , platelet &lt; 100,000/mm³ , WBC &lt; 2,000 Active pulmonary disease require medication include multiple inhaler Patients may receive investigational agent ( except permission Lead Principal Investigator ) Pregnant nursing History autoimmune disease ( patient vitiligo exclude ) HIV positive Previous concomitant malignancy sit , except effectively treat non melanoma skin cancer carcinoma situ cervix effectively treat malignancy remission 5 year highly likely cure Other concurrent severe medical problem , unrelated malignancy , would significantly limit full compliance study expose patient unacceptable risk Uncontrolled congestive heart failure hypertension , unstable heart disease ( coronary artery disease myocardial infarction ) uncontrolled arrhythmia time enrollment Psychiatric , addictive , disorder compromise ability give truly informed consent participation study adequate compliance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>